within Pharmacolibrary.Drugs.ATC.L;

model L03AA02
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 1.1833333333333332e-05,
    adminDuration  = 600,
    adminMass      = 375 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.00023999999999999998,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.00049,
    k12             = 0.049,
    k21             = 0.049
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L03AA02</td></tr><td>route:</td><td>subcutaneous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Filgrastim is a recombinant human granulocyte colony-stimulating factor (G-CSF) that stimulates the production of neutrophils. It is used for the prevention and treatment of neutropenia in patients undergoing chemotherapy, bone marrow transplantation, or with severe chronic neutropenia. Filgrastim is approved and in current clinical use.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers after subcutaneous administration. Typical patient population: adult, healthy, both sexes.</p><h4>References</h4><ol><li><p>Yang, BB, &amp; Kido, A (2011). Pharmacokinetics and pharmacodynamics of pegfilgrastim. <i>Clinical pharmacokinetics</i> 50(5) 295–306. DOI:<a href=\"https://doi.org/10.2165/11586040-000000000-00000\">10.2165/11586040-000000000-00000</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/21456630/\">https://pubmed.ncbi.nlm.nih.gov/21456630</a></p></li><li><p>Stewart, AW, et al., &amp; Cumpston, A (2022). A prospective study of filgrastim pharmacokinetics in morbidly obese patients compared with non-obese controls. <i>Pharmacotherapy</i> 42(1) 53–57. DOI:<a href=\"https://doi.org/10.1002/phar.2646\">10.1002/phar.2646</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/34767652/\">https://pubmed.ncbi.nlm.nih.gov/34767652</a></p></li><li><p>Yao, HM, et al., &amp; Summers, M (2019). PF-06881893 (Nivestym™), a Filgrastim Biosimilar, Versus US-Licensed Filgrastim Reference Product (US-Neupogen. <i>BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy</i> 33(2) 207–220. DOI:<a href=\"https://doi.org/10.1007/s40259-019-00343-8\">10.1007/s40259-019-00343-8</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/30900158/\">https://pubmed.ncbi.nlm.nih.gov/30900158</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L03AA02;
